NASDAQ:HOTH - Hoth Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.54
▼ -0.07 (-4.35%)
1 month | 3 months | 12 months
Get New Hoth Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HOTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HOTH

Average Price Target: $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Hoth Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.54.

N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Hoth Therapeutics. This rating has held steady since September 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/15/2019BenchmarkInitiated CoverageSpeculative Buy$10.00High
5/20/2019LaidlawInitiated CoverageBuy$10.00Low
(Data available from 6/20/2016 forward)

Hoth Therapeutics

Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SARS-CoV-2 infection; HT-003D for the topical treatment in acne and psoriasis applications; HT-003IB to treat inflammatory bowel diseases; HT-004 for the treatment of asthma, atopic dermatitis, and other allergic diseases; HT-005 Z-PODS to treat cutaneous lupus erythematosus; HT-006 for treatment of multiple bacterial pathogens. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with Zylö Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life; and research collaboration agreement with Weill Cornell Medicine to continue the advancement of HT-003 for acne treatment research. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Read More

Today's Range

Now: $1.54
Low: $1.52
High: $1.65

50 Day Range

MA: $1.51
Low: $1.31
High: $1.75

52 Week Range

Now: $1.54
Low: $1.27
High: $3.89

Volume

717,738 shs

Average Volume

3,293,503 shs

Market Capitalization

$36.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Hoth Therapeutics?

The following Wall Street analysts have issued reports on Hoth Therapeutics in the last year: Zacks Investment Research.
View the latest analyst ratings for HOTH.

What is the current price target for Hoth Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Hoth Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Hoth Therapeutics in the next year.
View the latest price targets for HOTH.

What is the current consensus analyst rating for Hoth Therapeutics?

Hoth Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HOTH.

What other companies compete with Hoth Therapeutics?

How do I contact Hoth Therapeutics' investor relations team?

Hoth Therapeutics' physical mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company's listed phone number is 646-756-2997 and its investor relations email address is [email protected] The official website for Hoth Therapeutics is www.hoththerapeutics.com.